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Abstract
Metabolomics is a relatively new and rapidly growing area of post-genomic biological research. 
As use of metabolomics technology grows throughout the spectrum of drug discovery and 
development, and its applications broaden, its impact is expanding dramatically. This review seeks 
to provide the reader with a brief history of the development of metabolomics, its significance and 
strategies for conducting metabolomics studies. The most widely used analytical tools for 
metabolomics: NMR, LC–MS and GC–MS, are discussed along with considerations for their use. 
Herein, we will show how metabolomics can assist in pharmaceutical research studies, such as 
pharmacology and toxicology, and discuss some examples of the importance of metabolomics 
analysis in research and development.
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History
Metabolic profiling is not new; it has been used for clinical detection of human disease using 
blood and urine samples for centuries. In the days when people consulted with astrologers, 
or were diagnosed via combinations of their ‘humours’, the medical analysis of urine was 
the gold standard. The urine wheel from Epiphanie Medicorum by Ullrich Pinder in 1506 
was the first application of crude science in medicine [1]. The urine wheel was used for 
diagnosing diseases based on the color, smell and taste of a patient’s urine in the early 16th 
century (Figure 1). The different colors and tastes of urine are due to mixtures of different 
*Corresponding author: Nassar, A.F. (ala.nassar@yale.edu).†An internship student (Summer 2016).
Conflicts of interest
The authors declare no conflict of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
Drug Discov Today. Author manuscript; available in PMC 2018 February 01.
Published in final edited form as:
Drug Discov Today. 2017 February ; 22(2): 463–470. doi:10.1016/j.drudis.2016.11.020.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
inorganic salts and organic compounds that the body excretes as soluble waste. Diabetes 
mellitus was originally identified by the taste of sweet urine. Diagnostics through taste and 
smell might be a low-tech metabolomics approach but diabetes mellitus has been firmly 
linked to glucose metabolism ever since. After this original discovery type 2 diabetes and 
some subgroups of diabetes mellitus were identified.
Ancient Arab, Hindu and Chinese texts also have anecdotal reports of the same sweet taste 
in urine from patients who displayed the symptoms of what was later termed diabetes. Urine 
wheels had been a standard inclusion in medical texts for centuries, and were gradually 
replaced by tables, test strips and microscope slides. Advanced chromatographic separation 
techniques were developed in the late 1960s. Linus Pauling published quantitative analysis 
of urine vapor and breath by gas–liquid partition chromatography in 1971 [2]. In the early 
1970s gas chromatography–mass spectrometry (GC–MS) technologies were used to analyze 
steroids, acids and neutral and acidic urinary drug metabolites [3]. Metabolic profiling using 
GC–MS was reported [4,5]. Metabolic profiling studies were first applied to toxicology, 
pharmacology, inborn metabolic errors and nutritional function.
During the past two decades, great interest has developed in the application of metabolomics 
to characterize different pathological states of human diseases like cancer, diabetes, 
autoimmune and coronary diseases, among others. Metabolomics can provide valuable tools 
in a wide range of applications, such as pharmacology, toxicology, enzyme discovery and 
systems biology. As early as 2000, metabolomics was offered as a new technique with the 
potential to provide faster toxicity screening in pharmaceuticals; by 2005, five 
pharmaceutical firms and the Imperial College of Science, Technology and Medicine in 
London formed the Consortium for Metabonomic Toxicology (COMET) [6]. Their work 
established a metabolomics database that has expanded over the years, and is invaluable to 
their research, and its use has expanded to other areas such as chemical industry toxicology 
testing. The Metabolomics Society provides lists of available databases such as 
comprehensive metabolomic, metabolic pathway, compound or compound-specific, drug, 
spectral and disease and physiology databases (http://metabolomicssociety.org/resources/
metabolomics-databases).
Significance of metabolomics
As these databases are expanded and refined, as well as our techniques and tools, this 
rapidly developing discipline is becoming a vital force, with the potential to transform 
pharmaceutical research. The value of metabolomics arises from the wide diversity of small 
molecules which, individually or in combinations, gives specific profiles for different human 
conditions including infectious, neoplastic, cardiovascular, neurological, metabolic and 
inflammatory diseases [7–9]. Metabolomics studies can help us to enhance our 
understanding of disease mechanisms and drug effects, as well as improving our ability to 
predict individual variation in drug response phenotypes [10–12]. Owing to its noninvasive 
nature, and close link with the phenotype, metabolomics is ideal for pharmaceutical 
research. For example, drug safety screens and biomarker discovery have already enhanced 
informed decision making. Personalization of analysis and treatment promises to allow us to 
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track our own metabolome, with potential to target specific biomarkers, which will improve 
treatment strategies.
Animal models are an essential tool for researchers hoping to learn more about metabolic 
disease. In many cases, data cannot be collected from living patients with a metabolic 
disease, because this sometimes calls for organ dissection or other highly invasive 
procedures. Model animals can be engineered to express the disease phenotype and can be 
euthanized to collect data. This overcomes a major difficulty in collecting data from living 
patients; there is no need for dangerous and destructive invasive procedures such as organ 
dissection. As an example, one research group successfully developed a means of 
monitoring asthma status by metabolomics and urine sampling. They hypothesized NMR 
could be utilized to detect and analyze the unique patterns of urine metabolites produced 
during various states of airway dysfunction and inflammation, and subsequently measured 
by multivariate statistical analysis. Five groups of guinea pigs were studied: control, control 
treated with dexamethasone, sensitized (ovalbumin, administered intraperitoneally), 
sensitized and challenged (ovalbumin, administered intraperitoneally, plus ovalbumin 
aerosol), and sensitized–challenged with dexamethasone. For each group, the researchers 
measured airway hyper-reactivity (AHR) to histamine (administered intravenously) and 
inflammation. Their work showed that the challenged guinea pigs developed AHR and 
increased inflammation compared with sensitized or control animals, and that 
dexamethasone significantly improved AHR. This study demonstrates that urine metabolites 
correlate with airway dysfunction in an asthma model, making urine NMR analysis a 
promising, noninvasive technique for monitoring asthma in humans [13].
Study workflow design
Figure 1 shows a proposed metabolomic strategy. After metabolism quenching, LC–MS data 
are acquired, followed by retention time correction data for chromatogram alignment and 
visualization of dysregulated metabolite features. Metabolite features whose levels were 
significantly changed in disease vs control samples are then filtered out and identified by 
MS/MS matching. The identified metabolites are quantified by targeted multiple reaction 
monitoring (MRM) analysis using standard compounds [14].
Sample preparation is one of the most important factors that determine the quality of 
metabolomics data [15]. Sampling affects the observed metabolite content and biological 
interpretation of the data. An ideal sample preparation method for global metabolomics 
should be as nonselective as possible to ensure adequate depth of metabolite coverage. Also, 
the best method will avoid metabolite loss and degradation during preparation, facilitate high 
throughput and be highly reproducible. A procedure that requires a minimum of steps, as 
well as the shortest practicable time, will help the researcher achieve these goals. One step 
that cannot be overlooked, in order to provide the most accurate metabolomics composition 
at the time of sampling, is that of metabolic quenching. Sample preparation methods must be 
able to facilitate the analysis of a variety of biological fluids, such as blood, urine, sputum, 
cerebrospinal fluid (CSF) and exhaled breath condensate in humans, or bacterial sources 
such as culture media. Urine is a more common matrix that requires relatively little sample 
preparation. For MS analysis, this involves dilution followed by centrifugation to remove 
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particulates. Serum and plasma are two other relevant and highly valuable matrices that have 
long been used in diagnostic, health and drug monitoring studies. Preparation for ultra 
performance liquid chromatography (UPLC)–MS metabolomics analysis involves a 
methanolic protein precipitation technique, which is simple and effective in extracting all 
classes of metabolites present in serum or plasma samples. One advantage of using urine or 
plasma in drug toxicology experiments is that the sample is collected noninvasively so that it 
can be applied in clinical studies. Another advantage is that multiple biofluid samples from a 
single subject can be collected over a time course, which allows the determination of a 
metabolic trajectory that describes the toxic response and recovery period. The analysis of 
metabolites in biofluids permits a toxicological evaluation of the health of many different 
organs within the same animal over time and could allow simultaneous evaluation of drug 
efficacy from the same biofluid sample.
Thus, a successful protocol will allow removal of unwanted proteins and other particulates 
while retaining hydrophobic and hydrophilic metabolites, and quenching of the metabolism, 
at which point the samples are ready for analysis. Although the majority of the work done in 
pharmaceutical labs is on peripheral biofluids that can be obtained noninvasively, there are 
times when tissue metabolomics is essential to complete understanding of the system under 
study. There are a number of methods that are routinely employed to physically lyse cells, 
including mechanical disruption, liquid homogenization, high frequency sound waves, 
freeze/thaw cycles and manual grinding.
There are two approaches to metabolomics studies: targeted and untargeted. Target analysis 
has been applied for many decades and includes the determination and quantification of a 
small but rapidly expanding set of known metabolites using one particular analytical 
technique of best performance for the compounds of interest. Authentic standards are 
available in these studies. The untargeted approach is effectively used to identify a number 
of unknown metabolites by comparing the relative abundances of metabolites in multiple 
samples without prior identification [16,20]. The goals of untargeted metabolomics are to 
determine the metabolomic profiles of phenotypic diseases and healthy states, involving a 
complex set of genomic and proteomic changes. Untargeted metabolomics makes it possible 
to analyze hundreds of individual metabolites. Some applications of untargeted 
metabolomics include biomarkers, cardiovascular, diabetes and obesity disease research and 
drug discovery.
Platforms for metabolomics analysis
The most widely used analytical tools for metabolomic studies to identify large numbers of 
metabolites are proton NMR (1H-NMR) spectroscopy, GC–MS and LC–MS [16,20,21]. 
Hundreds of metabolites can be separated and measured in samples of interest such as 
plasma, CSF, urine or cell extracts using a diversity of commonly used metabolomics tools 
such as NMR, GC–MS and LC–MS detection. Each of these analytical tools carries its own 
advantages, disadvantages and applications as shown in Table 1 [22]. Table 1 shows the most 
common analytical tools for analysis of the various classes of compounds, such as lipids, 
carbohydrates, amino acids, organic acids, sugars, sugar phosphates, biogenic amines, 
nucleotides, vitamins, purines, fatty acids and steroids. It shows that no single tool is fit to 
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analyze all compounds; generally, a combination of two or three analytical platforms is 
needed to identify the various stages of a disease and to differentiate diseases. To have the 
desired statistical power, it is proposed that a minimum of three biological replicates is 
required and five replicates are preferred to obtain reliable data. Overall, NMR has 
advantages such as reproducibility, the nondestructive nature of sample preparation and the 
comprehensive coverage of chemical species, whereas MS possesses much better sensitivity 
and resolution as well as high-throughput capacity. NMR scores well in terms of 
reproducibility, whereas MS techniques have the advantage of significantly improved 
sensitivity (Table 1).
Considerations when using NMR, LC–MS or GC–MS
• Collection time for basic data: NMR 5 min; MS 10 min for UPLC–MS. More-
comprehensive LC–MS methods involve run times of ~30 min, with the potential 
to detect 200 metabolites. Run times for NMR are about the same, with the 
ability to quantify 50 metabolites in samples.
• The detection limits are in mg, ng, pg for NMR (600 MHz), LC–MS and GC–
MS, respectively.
• Metabolite detection: with NMR, if the metabolite contains hydrogen it will be 
detected assuming the concentration is sufficient and protein binding does not 
cause marked line-broadening. MS usually requires a more targeted approach. 
Although there can be problems with loss of metabolites in void volume with ion 
suppression, this is reduced when using UPLC. The ability to run negative and 
positive ion detection gives extra information. NMR cannot detect or identify 
salts and inorganic ions, whereas LC–MS and GC–MS can detect most organic 
and some inorganic molecules.
• Sample handling and analysis: using NMR, the whole sample is analyzed in one 
measurement with no destruction of the samples during analysis. LC–MS 
requires samples to be extracted into a suitable solvent, as well as specific LC 
conditions for different classes of metabolites, whereas GC–MS requires 
derivatization. For GC–MS and LC–MS the samples are not recoverable.
• Volume of sample required: NMR typically needs 200–400 μl; MS uses ~10 μl.
• Reproducibility: NMR and GC–MS are excellent for separation reproducibility 
whereas LC–MS is fair.
• Robustness: NMR and GC–MS are both robust and mature technologies; LC–
MS is less so.
• Analysis of tissue samples: NMR is compatible with liquids and solids, LC–MS 
can be used in metabolite imaging [matrix-assisted laser desorption/ionization 
(MALDI) or desorption electrospray ionization (DESI)], and GC–MS is 
compatible with gases and liquids.
• Quantitative: NMR can quantify a wide range of organic compounds; GC–MS 
and LC–MS need calibration standards for quantitative analysis.
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• Identification of novel chemicals: NMR works well and most spectral features 
are identifiable. For LC–MS and GC–MS novel compound identification is 
difficult.
• Instrument cost and lifetime: NMR has high costs >US$1 million; LC–MS is 
~US$500 000; and GC–MS is ~US$250 000. NMR instruments have a life time 
of over 20 years, LC–MS ~8 years and GC–MS >10 years.
Metabolomics in drug discovery
Metabolomics has been applied in preclinical drug development studies such as 
pharmacology, toxicology and ADME [23–25]. One example of the use of metabolomics 
involves investigation of the lipid expression patterns of six anti-inflammatory compounds 
using principal component discriminant analysis [26]. The research group studied the effects 
on the transcriptome, proteome and metabolome of macrophage-like U937 cells when they 
were exposed to various anti-inflammatory drugs, including β2-adrenergic agonists. Using 
LC–MS, profiles of choline derivatives were also determined, including 
lysophosphocholines, phosphocholines, triglycerides and cholesterol esters. The study 
showed that three β2-adrenergic agonists employed: zilpaterol, clenbuterol and salbutamol, 
produced similar choline derivative changes in U937 cells compared to dexamethasone and 
SB203580 (a specific inhibitor of the p38/MAPK pathway). Subsequently, the data were 
used to characterize the pharmacological effects of a group of anti-inflammatory drugs in 
terms of their effects on target cell transcriptome, proteome and metabolome. The study 
concluded that the tested drugs produced no important marker molecules [26]. Another 
group studied the changes in lysophospholipids noted in patients with nonalcoholic 
steatohepatitis (NASH), which were consistent with changes that have been noted in 
hepatocellular carcinoma, showing a potential mechanistic progression pathway from NASH 
to carcinoma [27].
The pharmacology phase is one of the key components of the drug discovery process. Drugs 
fail in clinical trials because they either do not work or are not safe to patients. The 
prediction of therapeutic efficacy and adverse event risk on an individual patient basis 
through systems pharmacology is believed to have promise in reducing failure rates in Phase 
II and III clinical trials. In one such study, NMR was used to detect metabolic changes in 
cells and provide information about the mechanism of action of antimicrobial agents. In this 
study it was reported that, by using the mutant strain Aspergillus nidulans uaZ14 mutant and 
comparative NMR metabolomics data, 8-azaxanthine inhibits A. nidulans hyphal growth by 
in vivo inactivation of urate oxidase [28]. As another example, metabolomics research 
provided more-comprehensive information on pharmacogenetic metabolic phenotypes, such 
as the urinary metabolic pattern obtained after the administration of debrisoquine, as well as 
the phenotype for CYP2D6 polymorphism [29,30]. Metabolomic studies were employed to 
investigate urine of wild-type and Farnesoid X receptor (Fxr)-null mice fed cholic acid, an 
FXR ligand, using UPLC–MS. The studies revealed that several metabolites of 
corticosterone and cholic acid had been highly elevated in Fxr-null mice by cholic acid 
loading but not in wild-type mice [31].
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Toxicity is a leading cause of attrition at all stages of the drug development process. Early 
indicators of drug safety are of intense interest to the pharmaceutical industry, which set up 
the Predictive Safety Testing Consortium comprising over 120 scientists from 16 drug 
companies who examine preclinical biomarkers for drug safety [32]. It has been estimated 
that the drug industry spends US$30 million a year in research to validate biomarkers for 
preclinical toxicity [33]. Also, it has been stated that predictive safety tests currently 
developed by individual companies are not useful to the agency because they have not been 
validated by an independent party. Metabolic profiling has the potential to identify toxicity 
early in the drug discovery process, which can save time and money for pharmaceutical 
companies [34].
Metabonomics methods were used in a preclinical study on a compound known to cause 
hepatotoxicity in several species [35]. NMR spectra were acquired on urine and liver tissue 
samples obtained from rats administered either a vehicle or a developmental compound 
(MrkA) that was shown to induce hepatotoxicity in several animal species. Results showed 
that urinary dicarboxylic aciduria is associated with defective metabolism of fatty acids; 
subsequent in vitro experiments confirmed that MrkA impairs fatty acid metabolism. 
Characterization of the urinary metabonome was the key step in rapidly ascertaining the 
probable mechanism of toxicity and led to the development of appropriate in vivo and in 
vitro experiments confirming that MrkA impaired fatty acid metabolism. This is a case 
where metabonomics was able to provide mechanistic insight to the hepatotoxicity of a drug 
[35].
Examples of the value of metabolomics analysis
An early diagnosis is crucial to reduce cancer mortality rates. In a recent study, a total of 58 
human serum metabolites were collected from 15 esophageal cancer patients, 11 gastric 
cancer patients, 12 colorectal cancer patients and 12 healthy volunteers. Of these metabolites 
the resulting GC–MS chromatograms showed differences in levels for each type of cancer 
compared with those of the healthy group [36]. In another study [37], an untargeted 
approach was used to analyze the relative metabolite concentrations between pancreatic 
cancer patients and healthy controls by high-resolution, flow-injection Fourier transform ion 
cyclotron MS. Several metabolites including serum phospholipids and novel ultra-long-chain 
fatty acids showed significantly altered levels between diseased and healthy volunteers. Both 
of these studies are examples of detecting biomarker panels instead of a single target, which 
represents a systems approach in solving complex diseases.
The current state of testing for metabolic diseases like type 2 diabetes mellitus involves 
prognostic and diagnostic biomarkers, such as the oral glucose tolerance test and blood 
glucose level, which are well-defined. Insulin deficiency is an indicator that diabetes has 
probably already started; what is lacking is a set of biomarkers that can predict or detect the 
onset of such diseases. Metabolomics research has shown that early indications of type 2 
diabetes include impaired glucose and amino acid and fatty acid metabolism. Wang et al. 
[38] studied alterations in amino acids over a 12-year period; their work produced a potential 
biomarker panel of amino acids which can detect those that were altered when compared 
with otherwise healthy volunteers. Because this alteration begins well before the onset of 
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insulin depletion, such a panel has the potential to prove invaluable in identifying diabetes 
long before its onset.
Cancer is one of the leading causes of death in the world. Currently nearly 15 million people 
in the USA are either living with cancer or are cancer survivors [38]. In 2015 more than 1.65 
million Americans will be diagnosed with cancer and 590 000 will die from it. Because 
cancer is such a widespread, pernicious disease that requires significant, long-term medical 
intervention, the economic costs are considerable. Current estimates of the cost of cancer 
care in the USA are pegged at US$150 billion per year and are expected to rise to nearly US
$173 billion per year by 2020. Cancer is widely known as a genetic disease arising from 
mutations in key oncogenes or tumor suppressors. Table 2 outlines cancer and the discovery 
of oncometabolites. Oncometabolites are endogenous metabolites and their accumulation 
initiates or sustains tumor growth and metastasis [39]. The first oncometabolite to be 
discovered was 2-hydroxyglutarate, a natural metabolite that is found in high concentrations 
in gliomas. This compound seems to indirectly alter histone methylation patterns, which 
ultimately leads to tumorigenesis. Since the discovery of 2-hydroxyglutarate, many other 
oncometabolites have been identified. Another example is methionine; the mechanism of its 
possible antihepatotoxic activity is not entirely clear. High doses of acetaminophen in the 
liver are thought to lead to decreased levels of hepatic glutathione and increased oxidative 
stress. Antioxidant activity of L-methionine and some of its metabolites appear to account 
for its possible antihepatotoxic activity. L-methionine is a precursor to L-cysteine, which by 
itself can have antioxidant activity. L-cysteine, in turn, is a precursor to the antioxidant 
glutathione. Recent research also suggests that methionine acts as a free-radical scavenger 
by virtue of its sulfur, as well as its chelating ability (http://www.drugbank.ca/drugs/
DB00134).
Sarcosine was reported to activate prostate cancer cells and to indicate the malignancy of 
prostate cancer cells when measured in urine [40]. However, this conclusion has been 
disputed. A German research team reported a different result in 2010. After measuring 
sarcosine levels in urine samples from prostate cancer patients, they concluded that 
measuring sarcosine in urine fails as a marker in prostate cancer detection and identification 
of aggressive tumors. In addition, another report concluded that serum sarcosine is not a 
marker for prostate cancer. A review of the literature reached a similar conclusion [40]. 
When metformin was combined with tamoxifen the concentration of tamoxifen required for 
growth inhibition was substantially reduced. It shows that metformin and tamoxifen 
additively inhibited the growth and augmented the apoptosis of estrogen receptor (ER)-
positive breast cancer cells. It provides leads for future research on this drug combination for 
the treatment of ER-positive breast cancer [41].
One recent example from our lab involves deciphering the effects of chemical exposures, 
which could ultimately help identify potential targets for preventing exposure-induced 
illness or post-exposure therapeutics. As a first step in our investigation, we undertook in 
vitro studies with the chemical allergen hexemethylene diisocyanate (HDI), which is well-
recognized to cause occupational asthma. We assayed for changes in 472 lipid and 148 polar 
metabolites in the human monocyte-like cell line (U937) following incubation for 48 h in the 
presence or absence of HDI (pre-reacted with albumin to create antigenic changes) [42]. The 
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relative change in the level of each of the different lipid and polar metabolites is depicted in 
Figures 3 and 4. As shown, HDI exposure caused substantial increases in trigylcerides and 
certain ceramides, but not other (e.g., phosho) lipids. Notably, the levels of the specific 
triglyceride (TG22:4/22:6/22:6) were over 100-fold increased whereas the levels of the 
phosphocholine (PC 26:0) were over 100-fold downregulated. Changes in polar metabolites 
included nearly tenfold increases in guanosine and carnosine, concomitant with relative 
decreases in ribose-1-phosphate. Further analyses of metabolite changes induced by HDI 
and other chemical exposures should help elucidate the pathways by which these exposures 
cause disease, and might identify targets for prevention and/or therapy.
Concluding remarks
Metabolomics is an emerging field with tremendous potential to improve our understanding 
of human health and disease, leading to the development of personalized approaches for 
disease diagnosis, patient monitoring and treatment response evaluation. Metabolomics has 
the potential to make a powerful impact in pharmaceutical and clinical research, including 
the identification of new targets, the elucidation of the mechanism of action of new drugs, 
the development of safety and efficacy profiles, as well as the discovery of biomarkers for 
early disease diagnosis and treatment. In addition, the identification and characterization of 
new biomarkers will allow early diagnosis and prevention of many diseases, as well as the 
discovery of new drugs.
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Teaser
The field of metabolomics is continually growing with our knowledge base of 
metabolites, analytical tools and bioinformatics approaches to analyze data. This rapidly 
developing new discipline has important potential implications for the pharmaceutical 
industry.
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Highlights
• Metabolomics provides a very powerful tool in pharmaceutical and clinical 
research
• Metabolomic biomarkers can improve personalized treatments
• Metabolomics can help us understand drug candidate actions and target 
selection
• Biofluid testing can facilitate the diagnosis and evaluation of treatment 
response
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Figure 1. 
Urine Wheel for diagnosing metabolic diseases, from Epiphanie Medicorum by Ullrich 
Pinder, 1506. Reproduced, with permission, from Scientific American Blog Network http://
blogs.scientificamerican.com/oscillator/the-urine-wheel/.
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Figure 2. 
Metabolomic workflow. Global profiling summarizes the experimental design with respect 
to metabolism quenching and global LC–MS profiling of different sample groups. LC–MS 
data acquisition is followed by retention time correction for chromatogram alignment and 
visualization of dysregulated metabolite features. Metabolite features where levels were 
significantly changed in disease vs control samples are then filtered out and identified by 
MS/MS matching. The identified metabolites are quantified by targeted multiple reaction 
monitoring (MRM) analysis using standard compounds. Reproduced, with permission, from 
permission from [14].
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Figure 3. 
Changes in lipid metabolites induced by occupational allergen. U937 cells were incubated 
with hexemethylene diisocyanate (HDI)-conjugated human serum albumin for 48 h and the 
levels of different lipid metabolites were expressed as a ratio relative to control samples. 
Each dot represents a different lipid metabolite: 1–17 (ceramides); 18–24 (diglycerides); 25–
37 (lysophosphatidylcholine); 38 (monoacylglyceride); 39–152 (phosphatidyl choline); 153–
222 (phosphoethanolamine); 223–224 (phosphoglycerols); 225–235 (phosphatidylinositol); 
236–238 (phosphoserines); 239–257 (phosphosphingolipids); 257–472 (triglycerides).
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Figure 4. 
Changes in polar metabolites induced by occupational allergen. U937 cells were incubated 
with hexemethylene diisocyanate (HDI)-conjugated human serum albumin for 48 h and the 
levels of different polar metabolites were expressed as a ratio relative to control samples. 
Each dot represents a different polar metabolite. Note the increase in guanosine and 
carnosine and decrease in ribose-1-phosphate.
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